Riyadh - Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) registered a 5.13% year-on-year (YoY) rise in net profit to SAR 416.05 million during the first nine months (9M) of 2026.
The growth was supported by a 7.13% increase in total revenue to SAR 1.28 billion, underpinned by strong sales volumes in Saudi Arabia and Iraq, alongside robust performance in the ophthalmology and dermatology segments.
Earnings per share (EPS) climbed to SAR 5.94. Total shareholders' equity stood at SAR 1.83 billion, up 10.58% compared to the previous year.
In the third quarter (Q3) of 2026, the company posted a net profit of SAR 110.21 million, up 3.32% from the same period last year.
Quarterly revenue reached SAR 354.66 million, a 3.61% increase. The company noted that while seasonal factors and geopolitical conditions impacted sequential performance, year-on-year gains were maintained through production efficiencies and an improved product mix.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) for the nine months reached SAR 477 million, representing a margin of 37.2%.
Jamjoom Pharma updated its full-year 2026 revenue growth guidance to a range of 7-9% and maintained a dividend payout ratio target of 50-60%.
At the end of June 2026, the pharmaceutical manufacturer’s revenue hiked by 12.39% YoY to SAR 445.31 million.
